Cargando…
Corneal Findings Associated to Belantamab-Mafodotin (Belamaf) Use in a Series of Patients Examined Longitudinally by Means of Advanced Corneal Imaging
Belantamab mafodotin (belamaf) is a novel antibody–drug conjugate developed for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). Although the drug has demonstrated a good efficacy, corneal adverse events have been reported. In this prospective study, consecutive patient...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147189/ https://www.ncbi.nlm.nih.gov/pubmed/35629012 http://dx.doi.org/10.3390/jcm11102884 |
_version_ | 1784716746986356736 |
---|---|
author | Mencucci, Rita Cennamo, Michela Alonzo, Ludovica Senni, Carlotta Vagge, Aldo Ferro Desideri, Lorenzo Scorcia, Vincenzo Giannaccare, Giuseppe |
author_facet | Mencucci, Rita Cennamo, Michela Alonzo, Ludovica Senni, Carlotta Vagge, Aldo Ferro Desideri, Lorenzo Scorcia, Vincenzo Giannaccare, Giuseppe |
author_sort | Mencucci, Rita |
collection | PubMed |
description | Belantamab mafodotin (belamaf) is a novel antibody–drug conjugate developed for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). Although the drug has demonstrated a good efficacy, corneal adverse events have been reported. In this prospective study, consecutive patients with RRMM who received belamaf infusions were included. The standard ophthalmological visit was implemented with anterior segment (AS)-optical coherence tomography (OCT) and in vivo confocal microscopy (IVCM). Five patients (three males, two females; mean age 66 ± 6.0 years) with MMRR and unremarkable ocular findings at baseline who received belamaf infusion were included. After a median time of 28 days from the first infusion, four of them developed corneal alterations with transient vision reduction to a variable extent. In particular, corneal deposits of microcyst-like epithelial changes (MECs) were detected centrally in one patient and peripherally in three patients. AS-OCT scans showed a bilateral heterogeneous increase in signal intensity, together with hyper-reflective lesions confined within the epithelium in all cases, except for one case in which they also involved the stroma. Corneal maps showed a transient increase in epithelial thickness in the first phase that was followed by a diffuse decrease in the subsequent phase. IVCM scans showed MECs as hyper-reflective opacities located at the level of corneal epithelium, largely intracellular. Multimodal corneal imaging may implement the current clinical scale, helping us to detect corneal abnormalities in patients under belamaf therapy. This workup provides useful data for monitoring over time corneal findings and for optimizing systemic therapy. |
format | Online Article Text |
id | pubmed-9147189 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91471892022-05-29 Corneal Findings Associated to Belantamab-Mafodotin (Belamaf) Use in a Series of Patients Examined Longitudinally by Means of Advanced Corneal Imaging Mencucci, Rita Cennamo, Michela Alonzo, Ludovica Senni, Carlotta Vagge, Aldo Ferro Desideri, Lorenzo Scorcia, Vincenzo Giannaccare, Giuseppe J Clin Med Article Belantamab mafodotin (belamaf) is a novel antibody–drug conjugate developed for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). Although the drug has demonstrated a good efficacy, corneal adverse events have been reported. In this prospective study, consecutive patients with RRMM who received belamaf infusions were included. The standard ophthalmological visit was implemented with anterior segment (AS)-optical coherence tomography (OCT) and in vivo confocal microscopy (IVCM). Five patients (three males, two females; mean age 66 ± 6.0 years) with MMRR and unremarkable ocular findings at baseline who received belamaf infusion were included. After a median time of 28 days from the first infusion, four of them developed corneal alterations with transient vision reduction to a variable extent. In particular, corneal deposits of microcyst-like epithelial changes (MECs) were detected centrally in one patient and peripherally in three patients. AS-OCT scans showed a bilateral heterogeneous increase in signal intensity, together with hyper-reflective lesions confined within the epithelium in all cases, except for one case in which they also involved the stroma. Corneal maps showed a transient increase in epithelial thickness in the first phase that was followed by a diffuse decrease in the subsequent phase. IVCM scans showed MECs as hyper-reflective opacities located at the level of corneal epithelium, largely intracellular. Multimodal corneal imaging may implement the current clinical scale, helping us to detect corneal abnormalities in patients under belamaf therapy. This workup provides useful data for monitoring over time corneal findings and for optimizing systemic therapy. MDPI 2022-05-19 /pmc/articles/PMC9147189/ /pubmed/35629012 http://dx.doi.org/10.3390/jcm11102884 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Mencucci, Rita Cennamo, Michela Alonzo, Ludovica Senni, Carlotta Vagge, Aldo Ferro Desideri, Lorenzo Scorcia, Vincenzo Giannaccare, Giuseppe Corneal Findings Associated to Belantamab-Mafodotin (Belamaf) Use in a Series of Patients Examined Longitudinally by Means of Advanced Corneal Imaging |
title | Corneal Findings Associated to Belantamab-Mafodotin (Belamaf) Use in a Series of Patients Examined Longitudinally by Means of Advanced Corneal Imaging |
title_full | Corneal Findings Associated to Belantamab-Mafodotin (Belamaf) Use in a Series of Patients Examined Longitudinally by Means of Advanced Corneal Imaging |
title_fullStr | Corneal Findings Associated to Belantamab-Mafodotin (Belamaf) Use in a Series of Patients Examined Longitudinally by Means of Advanced Corneal Imaging |
title_full_unstemmed | Corneal Findings Associated to Belantamab-Mafodotin (Belamaf) Use in a Series of Patients Examined Longitudinally by Means of Advanced Corneal Imaging |
title_short | Corneal Findings Associated to Belantamab-Mafodotin (Belamaf) Use in a Series of Patients Examined Longitudinally by Means of Advanced Corneal Imaging |
title_sort | corneal findings associated to belantamab-mafodotin (belamaf) use in a series of patients examined longitudinally by means of advanced corneal imaging |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147189/ https://www.ncbi.nlm.nih.gov/pubmed/35629012 http://dx.doi.org/10.3390/jcm11102884 |
work_keys_str_mv | AT mencuccirita cornealfindingsassociatedtobelantamabmafodotinbelamafuseinaseriesofpatientsexaminedlongitudinallybymeansofadvancedcornealimaging AT cennamomichela cornealfindingsassociatedtobelantamabmafodotinbelamafuseinaseriesofpatientsexaminedlongitudinallybymeansofadvancedcornealimaging AT alonzoludovica cornealfindingsassociatedtobelantamabmafodotinbelamafuseinaseriesofpatientsexaminedlongitudinallybymeansofadvancedcornealimaging AT sennicarlotta cornealfindingsassociatedtobelantamabmafodotinbelamafuseinaseriesofpatientsexaminedlongitudinallybymeansofadvancedcornealimaging AT vaggealdo cornealfindingsassociatedtobelantamabmafodotinbelamafuseinaseriesofpatientsexaminedlongitudinallybymeansofadvancedcornealimaging AT ferrodesiderilorenzo cornealfindingsassociatedtobelantamabmafodotinbelamafuseinaseriesofpatientsexaminedlongitudinallybymeansofadvancedcornealimaging AT scorciavincenzo cornealfindingsassociatedtobelantamabmafodotinbelamafuseinaseriesofpatientsexaminedlongitudinallybymeansofadvancedcornealimaging AT giannaccaregiuseppe cornealfindingsassociatedtobelantamabmafodotinbelamafuseinaseriesofpatientsexaminedlongitudinallybymeansofadvancedcornealimaging |